BI 764532
Boehringer Ingelheim
['lung', 'sclc']
1: updates from #asco23! dr. martin wermke, md from shares about the first-in-human trial of bi 764532. this unique drug targets dll3 and cd3 in patients with dll3+ sclc and neuroendocrine carcinoma (nec). #lungcancer #nec 
🫁Pneumo-Onco🩺 Chef de Pôle de Méd à Orientation Onco 🏥 @CHToulonLaSeyne 🔬Conseil Scientifique @IFCTLung / Pdte du 3C VarOuest 👉🏼#HopitalPublic #LungCancer